Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$164.99 USD

164.99
4,600,299

-2.37 (-1.42%)

Updated Sep 5, 2024 04:00 PM ET

After-Market: $164.96 -0.03 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Intra-Cellular (ITCI) Q2 Earnings & Sales Top, '23 View Raised

Intra-Cellular (ITCI) reports better-than-expected second-quarter results. Caplyta sales continue to drive growth. The company raises its financial outlook for full-year Caplyta sales.

The Zacks Analyst Blog Highlights Johnson & Johnson, General Dynamics, Pioneer Natural Resources, Alibaba Group and Autodesk

Johnson & Johnson, General Dynamics, Pioneer Natural Resources, Alibaba Group and Autodesk are part of the Zacks top Analyst Blog.

Sanghamitra Saha headshot

Looking to Bet On Perfect AAA Credit Ratings? Play These ETFs

In light of Fitch Ratings' downgrade of U.S. credit, investors might be interested in identifying companies and countries that still hold the desirable 'AAA' credit rating.

Sheraz Mian headshot

Q2 Earnings Season Scorecard and Research Reports for JNJ, Pioneer Natural & Others

Today's Research Daily features a real-time Q2 scorecard and updated reports on JNJ (JNJ), General Dynamics (GD), Pioneer Natural Resources (PXD) and others.

Editas' (EDIT) Q2 Earnings Beat, Sales Miss, Pipeline in Focus

Editas (EDIT) reports mixed second-quarter 2023 results. EDIT-301 studies remain on track to provide updates by the end of the year. The stock of the company rises about 6% on Wednesday.

Sarepta (SRPT) Q2 Loss Narrower Than Expected, Sales Miss

Sarepta's (SRPT) second-quarter 2023 earnings beat estimates. Though total revenues register strong year-over-year growth during the quarter, the same misses the mark.

Allogene's (ALLO) Q2 Loss Narrower Than Expected, Sales Miss

Allogene's (ALLO) second-quarter results beat estimates for earnings but misses the mark on sales. Management reiterated its previously-issued financial guidance for 2023.

Moderna (MRNA) Beats on Q2 Earnings & Sales, Raises '23 View

Moderna (MRNA) beats expectations for earnings and sales. Management raises its product revenue guidance based on potential U.S. demand for COVID vaccines during the upcoming fall season.

Acadia (ACAD) Q2 Earnings & Revenues Beat Estimates, '23 View Up

Acadia (ACAD) reports better-than-expected second-quarter 2023 results, raising its financial guidance for the year. The company also provides updates on its pipeline.

Pacira (PCRX) Q2 Earnings and Sales Miss, '23 View Updated

Pacira (PCRX) announces weaker-than-expected second-quarter 2023 results. The company updates its 2023 financial guidance.

Blueprint (BPMC) Q2 Earnings and Revenues Beat Estimates

Blueprint (BPMC) reports better-than-expected second-quarter 2023 results, driven by increased Ayvakit sales, following FDA approval in a new indication.

United Therapeutics (UTHR) Q2 Earnings & Sales Beat Estimates

United Therapeutics' (UTHR) second-quarter 2023 earnings and sales beat estimates. Tyvaso sales continue to drive the company's top line.

Vertex (VRTX) Beats on Q2 Earnings & Sales, Raises '23 View

Vertex Pharmaceuticals' (VRTX) second-quarter 2023 earnings and sales beat estimates. Based on strong Trikafta uptake, management raises its financial guidance for 2023.

Merck (MRK) Beats on Q2 Earnings and Sales, Ups 2023 View

Merck (MRK) beats Q2 estimates for earnings and sales. It raises its 2023 guidance. Stock rises in pre-market.

Apellis (APLS) Q2 Earnings Top, Syfovre Sales Boost Revenues

Apellis (APLS) reports better-than-expected second-quarter 2023 results. However, the stock falls 20% due to ambiguity surrounding Syfovre's safety profile.

Company News for Aug 1, 2023

Companies in The News Are: XOM, JNJ, ON, NFLX

Nalak Das headshot

Forget Soft Landing for Economy, Think About a New Takeoff

At this stage, we have narrowed our search to five stocks. These are: META, GOOGL, KO, PEP, JNJ.

Derek Lewis headshot

These 3 Quarterly Releases Positively Shocked the Market

There have been several notable surprises throughout the Q2 earnings season so far, including those from these three companies.

AstraZeneca (AZN) Q2 Earnings & Sales Beat, Nil COVID Sales

AstraZeneca (AZN) beats second-quarter estimates for earnings and sales. The company did not generate any revenues from COVID-19 medications. Management reaffirms its 2023 guidance.

Dorian and Oxford Industries have been highlighted as Zacks Bull and Bear of the Day

Dorian and Oxford Industries are part of the Zacks Bull and Bear of the Day article.

AbbVie (ABBV) Beats on Q2 Earnings & Sales, Raises '23 View

AbbVie's (ABBV) second-quarter 2023 earnings and sales beat estimates. The company raises its EPS guidance. Stock rises post the announcement.

Alkermes (ALKS) Q2 Earnings & Revenues Beat Estimates

Alkermes (ALKS) reports encouraging second-quarter results, wherein both earnings and revenues beat estimates. This is due to strong growth in commercial execution of its proprietary products, Lybalvi and Vivitrol.

Nalak Das headshot

Fed's July Rate Hike and Comments Match Expectations: 5 Picks

We have narrowed our search to five U.S. corporate behemoths. These are: META, GOOGL, ISRG, JNJ, PEP.

Tirthankar Chakraborty headshot

3 Top Blue Chip Stocks to Ride the Dow Rally

As the Dow continues to scale upward, it's prudent to invest in stocks such as JPMorgan (JPM), Walmart (WMT) and Johnson & Johnson (JNJ) that are listed on the said index and are financially sound.

Sanghamitra Saha headshot

Dow Jones ETFs Continue Winning Run as Rates at 2001 High

Fed raised its benchmark interest rate by 0.25% on Wednesday, leaving room for more hikes this year. Such rising rate environment is a plus for the Dow Jones ETFs.